Literature DB >> 17977031

Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation.

Katia Perruccio1, Fabiana Topini, Antonella Tosti, Alessandra Carotti, Teresa Aloisi, Franco Aversa, Massimo F Martelli, Andrea Velardi.   

Abstract

After haploidentical stem cell transplantation immune recovery is inevitably slow and infectious related mortality is about 30-40%. Immune reconstitution could be improved by infusing donor T cells, but the obstacle is graft-versus-host disease. In a mixed lymphocyte reaction, alloantigen-stimulated T cells uptake 4,5-dibromorhodamine methyl ester (TH9402), a compound that is structurally similar to rhodamine. TH9402 preferentially localizes in mitochondria and when exposed to 500- to 600-nm wavelength visible light delivered through the Theralux device (Kiadis Pharma, Amsterdam, The Netherlands), it becomes highly cytotoxic through oxidative damage. This study investigated a range of parameters, and combinations thereof, with the aim of achieving optimal T cell allodepletion and preservation of pathogen-specific responses. We report on 11 clinical scale dry runs which reproducibly yielded the following results. Blood mononuclear cells were stimulated with haploidentical irradiated (20 Gy). Blood mononuclear cells in a mixed lymphocyte reaction. Cells were then incubated with TH9402 and exposed to light delivered through the Theralux device. Optimal conditions for T cell allodepletion emerged as (1) duration of mixed lymphocyte reaction: 24 h; (2) responder cell concentration: 3-5x10(6)/ml; (3) TH9402 concentration: 5 microM; (4) quantity of internalized TH9402, as measured by mean fluorescence intensity (MFI): 20,000-25,000 MFI; (5) energy delivered: 0.1 J/cm(2). Only under these conditions were the frequencies (by limiting dilution analyses) of alloantigen-specific T cells maximally reduced, i.e., 2467+/-639 (mean+/-SD) times, when compared with non-TH9402-treated cells. Pathogen-specific responses to pathogen antigens such as Cytomegalovirus, Adenovirus, Varicella Zoster Virus, Herpes Simplex Virus, Aspergillus fumigatus, Candida albicans, Toxoplasma gondii were retained, although with a 19+/-9.7 times reduction in frequency. This remarkable drop in frequency of alloreactive T cells is expected to allow safe infusion of relatively large numbers of T cells across histocompatibility barriers for adoptive transfer of donor immunity. Consequently, a clinical trial is planned to incorporate infusion of photo-allodepleted donor T cells after haploidentical stem cell transplantation with the aim of decreasing infection-related mortality.

Entities:  

Mesh:

Year:  2007        PMID: 17977031     DOI: 10.1016/j.bcmd.2007.06.022

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  23 in total

1.  Strategies to harness immunity against infectious pathogens after haploidentical stem cell transplantation.

Authors:  Sergio Rutella; Franco Locatelli
Journal:  Am J Transl Res       Date:  2011-09-10       Impact factor: 4.060

2.  Induction of tolerance to bone marrow allografts by donor-derived host nonreactive ex vivo-induced central memory CD8 T cells.

Authors:  Eran Ophir; Yaki Eidelstein; Ran Afik; Esther Bachar-Lustig; Yair Reisner
Journal:  Blood       Date:  2009-12-30       Impact factor: 22.113

3.  T-cell depletion: from positive selection to negative depletion in adult patients.

Authors:  F Aversa
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 4.  Haploidentical vs cord blood transplantation for adults with acute myelogenous leukemia.

Authors:  Melhem Solh
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

5.  Murine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells.

Authors:  Eran Ophir; Noga Or-Geva; Irina Gurevich; Orna Tal; Yaki Eidelstein; Elias Shezen; Raanan Margalit; Assaf Lask; Guy Shakhar; David Hagin; Esther Bachar-Lustig; Shlomit Reich-Zeliger; Andreas Beilhack; Robert Negrin; Yair Reisner
Journal:  Blood       Date:  2012-12-05       Impact factor: 22.113

6.  A new approach for eradication of residual lymphoma cells by host nonreactive anti-third-party central memory CD8 T cells.

Authors:  Assaf Lask; Eran Ophir; Noga Or-Geva; Adva Cohen-Fredarow; Ran Afik; Yaki Eidelstein; Shlomit Reich-Zeliger; Bar Nathansohn; Matthias Edinger; Robert S Negrin; David Hagin; Yair Reisner
Journal:  Blood       Date:  2013-02-27       Impact factor: 22.113

Review 7.  Halfway there: the past, present and future of haploidentical transplantation.

Authors:  M Slade; B Fakhri; B N Savani; R Romee
Journal:  Bone Marrow Transplant       Date:  2016-07-25       Impact factor: 5.483

Review 8.  Cytotoxic T lymphocytes as immune-therapy in haematological practice.

Authors:  Ann M Leen; Helen E Heslop
Journal:  Br J Haematol       Date:  2008-08-07       Impact factor: 6.998

Review 9.  Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation.

Authors:  Leo Luznik; Paul V O'Donnell; Ephraim J Fuchs
Journal:  Semin Oncol       Date:  2012-12       Impact factor: 4.929

Review 10.  Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells.

Authors:  Conrad R Y Cruz; Catherine M Bollard
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.